THORLNC and urinary bladder carcinoma: Other studies highlight that both THOR hypermethylation and TERT promoter mutations are common and coexist in bladder cancer, and while TERT promoter mutation behaves as an early event in bladder carcinogenesis, THOR hypermethylation seems associated with disease progression, with the combined genetic and epigenetic alterations of TERT bringing additional prognostic value in NMIBC (Leão et al., 2019).